The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
Neoadjuvant Nivolumab/Ipilimumab Combo Effective but Toxic for Melanoma
November 12th 2017Neoadjuvant nivolumab plus ipilimumab demonstrated almost a tripling in objective response rate compared with the PD-1 inhibitor alone but at the cost of significant added grade 3 adverse events for patients with high-risk resectable melanoma.
JCAR015 Experience Informs Future CAR-T Studies
November 11th 2017The high rates of cerebral edema seen with JCAR015 in the phase II ROCKET trial were attributed to early and rapid chimeric antigen receptor (CAR)-modified T-cell expansion and a rise in interleukin-15 levels, a finding that could help inform future CAR T-cell usage.
Drake Highlights PARP Inhibitors, Immunotherapy in Prostate Cancer
November 8th 2017Charles Drake, MD, PhD, discusses the current status of both PARP inhibitors and immunotherapy in prostate cancer, emphasizing that immunotherapy is still very much a player in the prostate cancer field, with ongoing trials exploring checkpoint inhibitors.